Tango Therapeutics, Inc. (TNGX)
22.46
-0.30
(-1.32%)
USD |
NASDAQ |
Sep 04, 11:53
Tango Therapeutics Cash from Investing (Quarterly) : -445.97M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -445.97M |
| March 31, 2026 | 9.635M |
| December 31, 2025 | -135.72M |
| September 30, 2025 | 47.48M |
| June 30, 2025 | 16.78M |
| March 31, 2025 | 30.60M |
| December 31, 2024 | 52.06M |
| September 30, 2024 | 32.57M |
| June 30, 2024 | 12.70M |
| March 31, 2024 | -11.20M |
| December 31, 2023 | 33.85M |
| September 30, 2023 | -56.66M |
| Date | Value |
|---|---|
| June 30, 2023 | 32.69M |
| March 31, 2023 | 31.55M |
| December 31, 2022 | -12.60M |
| September 30, 2022 | 15.23M |
| June 30, 2022 | 35.49M |
| March 31, 2022 | -11.72M |
| December 31, 2021 | -45.21M |
| September 30, 2021 | -152.21M |
| June 30, 2021 | -6.625M |
| March 31, 2021 | 20.61M |
| December 31, 2020 | -59.21M |
| September 30, 2020 | -86.26M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Revolution Medicines, Inc. | -1.659B |
| Erasca, Inc. | 19.49M |
| NovelStem International Corp. | 0.00 |
| Brainstorm Cell Therapeutics, Inc. | 0.00 |
| Summit Therapeutics, Inc. | 222.41M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -38.87M |
| Cash from Financing (Quarterly) | 672.57M |
| Free Cash Flow | -144.27M |
| Free Cash Flow Per Share (Quarterly) | -0.2593 |
| Free Cash Flow to Equity (Quarterly) | -38.07M |
| Free Cash Flow to Firm (Quarterly) | -38.87M |
| Free Cash Flow Yield | -4.79% |